EP7-攻破 40 億美金市場！三藥聯合策略如何翻轉癌症二線治療 Disrupting a $4B Market: Triple-Combo Cancer Strategy

【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作

當 PD-1 抑制劑遇到瓶頸，誰能從免疫系統的「上游」點燃新的戰火？
為什麼「三藥聯合策略」不是單純的藥物加法，而是精密的黃金三角戰術？
當 HCB101 在頭頸癌單藥治療見到超過一年的持續反應，這對全球 40 億美金市場意味著什麼？
本集我們邀請到漢康生技的集團總裁暨醫療長——陸英明 博士（Alvin），深度解碼 HCB101 首度公開的驚人臨床數據，以及漢康如何佈局全球標準的轉譯醫學。

精彩內容：

• 三藥聯合的黃金三角： 為什麼在二線胃癌治療中，同時「拆除偽裝、切斷補給、直接攻堅」能產生 1+1+1>3 的臨床價值？

• 先天免疫的橋樑作用： 相比傳統針對 T 細胞的下游療法，HCB101 如何透過巨噬細胞從上游啟動免疫反擊？

• 數據背後的真相： 僅僅 6 週就看到腫瘤部分緩解（PR）代表什麼？臨床醫師如何解讀「持續性」與「一致性」？

• 跨越地理的全球標準： 從上海、台北到美國，漢康如何用單一全球標準（Global Standard）設計臨床試驗，對接 FDA 與 EMA 監管。

• 台灣生技的領航力： 為什麼 Alvin 認為台灣不僅有 R&D 實力，更有機會帶領生物醫藥創新走向國際終點線？

【About This Episode】
When PD-1 inhibitors hit a plateau, who can reignite the anti-cancer fight from the "upstream" of the immune system?
Why is a "Triple Combination Strategy" not just a simple addition of drugs, but a precisely engineered "Golden Triangle" tactic?
With HCB101 monotherapy showing sustained responses for over a year in head and neck cancer, what does this mean for a $4 billion global market?
In this episode, we are joined by Dr. Alvin Luk, President and Chief Medical Officer of HanchorBio. Dr. Luk provides a deep dive into the recently disclosed, astonishing clinical data for HCB101 and explains how HanchorBio is navigating global translational medicine with world-class standards.

【Key Takeaways】
The Golden Triangle of Triple Combination: Why does simultaneously "unmasking the tumor, cutting off supplies, and delivering direct cytotoxicity" create clinical value greater than the sum of its parts in second-line gastric cancer?
The Bridge of Innate Immunity: Compared to traditional therapies focusing on downstream T-cells, how does HCB101 activate the immune system from the upstream via macrophages?
Decoding the Data: What does comprehensive tumor shrinkage (PR, partial response) within just 6 weeks signify? How do clinicians evaluate "durability" and "consistency" in early-stage trials?
Global Regulatory Synergy: From Shanghai and Taipei to the U.S., how does HanchorBio utilize a single "Global Standard" for trial design to align with FDA and EMA expectations?
Taiwan’s Biotech Leadership: Why Dr. Luk believes Taiwan possesses not only the R&D foundation but also the potential to lead global biotech innovation to the finish line?

漢康生技官網：https://www.hanchorbio.com/
漢康生技LinkedIn：https://reurl.cc/7b19y9

本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。